CHARGED ALPHATMFrontier AI stock research

PFE · NYSE

Pfizer Inc.

Drug Manufacturers - General · United States

USD 27.660.1% daily changeQuote 2026-09-18 · USD
Market cap (USD)
US$157.65B
Trailing P/E
36.39x
Forward P/E
9.55x
Quarterly revenue growth
2.6%
Trailing net margin
6.8%
Indicated dividend yield
6.2%

Snapshot 2026-09-20 · Latest financial period 2026-06-28 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-11-03 (provider estimate, not issuer-confirmed).

Company background

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company website

Q2 2026

Go beyond the headline.

Pfizer (PFE): The Beat Was A Decline. And $3.8 Billion Of Pipeline Went To Zero.

Published 2026-08-06

Comparable businesses

PFE peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricPFEPfizer Inc.Snapshot 2026-09-20Financial period: 2026-06-28NVONovo Nordisk A/SSnapshot 2026-09-20Financial period: 2026-06-30BMYBristol-Myers Squibb CompanySnapshot 2026-09-20Financial period: 2026-06-30Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$157.65BUS$191.03BUS$128.81BUS$159.92Bn=2
Forward P/EProvider forward earnings estimate9.55x12.86x9.61x11.23xn=2
EV / EBITDAEnterprise value / trailing EBITDA8.26x8.60x
Revenue growthLatest quarter vs prior-year quarter2.6%2.1%5.7%3.9%n=2
Operating marginLatest reported quarter27.9%42.5%34.4%38.5%n=2
Free cash flow yieldTrailing cash flow / market cap7.9%6.3%
Net debt / EBITDANet debt / trailing EBITDA2.04x0.55x1.80x1.17xn=2
Debt / equityTotal debt / positive book equity0.74x0.63x2.02x1.33xn=2
Trailing P/ETrailing twelve-month earnings36.39x10.73x13.89x12.31xn=2
Price / bookPrice / positive book equity per share1.85x5.60x5.77x5.69xn=2
EV / salesEnterprise value / trailing revenue3.29x3.31x
Earnings growthLatest quarter vs prior-year quarter-20.6%153.1%66.2%n=2
Gross marginTrailing twelve months74.7%82.0%71.7%76.8%n=2
Net marginTrailing twelve months6.8%35.3%18.9%27.1%n=2
Return on equityProvider trailing return; positive equity only5.0%59.8%46.6%53.2%n=2
Free cash flow marginTrailing free cash flow / revenue19.6%11.4%16.5%14.0%n=2
Dividend yieldIndicated annual dividend / price6.2%4.2%4.0%4.1%n=2
Earnings payoutProvider trailing dividend payout226.3%44.5%55.3%49.9%n=2
Current ratioCurrent assets / current liabilities1.27x0.87x1.53x1.20xn=2
BetaProvider historical market sensitivity0.300.340.230.29n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for PFE

All available reporting periods
Q2 20262026-08-06
Q1 20262026-05-05
Q4 20252026-04-13

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.